{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T01:21:12Z","timestamp":1791249672520,"version":"4.1.0"},"reference-count":143,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T00:00:00Z","timestamp":1751587200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T00:00:00Z","timestamp":1751587200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11033-025-10754-2","type":"journal-article","created":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T04:07:20Z","timestamp":1751602040000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A review on current theories and potential therapies for prion diseases"],"prefix":"10.1007","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-3655-4689","authenticated-orcid":false,"given":"Saranya","family":"Udayakumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0475-2544","authenticated-orcid":false,"given":"Agnishwar","family":"Girigoswami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1554-5241","authenticated-orcid":false,"given":"Koyeli","family":"Girigoswami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,4]]},"reference":[{"key":"10754_CR1","doi-asserted-by":"crossref","first-page":"100106","DOI":"10.1016\/j.dscb.2023.100106","volume":"13","author":"SK Metkar","year":"2024","unstructured":"Metkar SK, Udayakumar S, Girigoswami A, Girigoswami K (2024) Amyloidosis-history and development, emphasis on insulin and prion amyloids. Brain Disord 13:100106","journal-title":"Brain Disord"},{"issue":"1","key":"10754_CR2","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12929-020-00636-z","volume":"27","author":"Y-Y Wu","year":"2020","unstructured":"Wu Y-Y, Kuo H-C (2020) Functional roles and networks of non-coding RNAs in the pathogenesis of neurodegenerative diseases. J Biomed Sci 27(1):49","journal-title":"J Biomed Sci"},{"key":"10754_CR3","doi-asserted-by":"crossref","unstructured":"Hong J-M, Moon J-H, Seol J-W, Park S-Y (2021) Melatonin-mediated Calcineurin inactivation attenuates prion Protein-induced Nf-Kb-Driven Pro-inflammation response","DOI":"10.21203\/rs.3.rs-1112914\/v1"},{"issue":"8","key":"10754_CR4","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1038\/s41594-022-00814-7","volume":"29","author":"K Frontzek","year":"2022","unstructured":"Frontzek K, Bardelli M, Senatore A, Henzi A, Reimann RR, Bedir S et al (2022) A conformational switch controlling the toxicity of the prion protein. Nat Struct Mol Biol 29(8):831\u2013840","journal-title":"Nat Struct Mol Biol"},{"key":"10754_CR5","doi-asserted-by":"crossref","unstructured":"Baldwin KJ, Correll CM (2019) Prion disease. Seminars in neurology;: Thieme Medical Publishers.","DOI":"10.1055\/s-0039-1687841"},{"key":"10754_CR6","doi-asserted-by":"crossref","first-page":"e62911","DOI":"10.7554\/eLife.62911","volume":"9","author":"C Scheckel","year":"2020","unstructured":"Scheckel C, Imeri M, Schwarz P, Aguzzi A (2020) Ribosomal profiling during prion disease uncovers progressive translational derangement in glia but not in neurons. Elife 9:e62911","journal-title":"Elife"},{"key":"10754_CR7","doi-asserted-by":"crossref","first-page":"648743","DOI":"10.3389\/fnins.2021.648743","volume":"15","author":"S Abu-Rumeileh","year":"2021","unstructured":"Abu-Rumeileh S, Parchi P (2021) Cerebrospinal fluid and blood neurofilament light chain protein in prion disease and other rapidly progressive dementias: current state of the art. Front Neurosci 15:648743","journal-title":"Front Neurosci"},{"issue":"14","key":"10754_CR8","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.3390\/ijms20143606","volume":"20","author":"L Bernardi","year":"2019","unstructured":"Bernardi L, Bruni AC (2019) Mutations in prion protein gene: pathogenic mechanisms in c-terminal vs n-terminal domain, a review. Int J Mol Sci 20(14):3606","journal-title":"Int J Mol Sci"},{"issue":"10","key":"10754_CR9","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/jcm.00769-19","volume":"57","author":"A Connor","year":"2019","unstructured":"Connor A, Wang H, Appleby BS, Rhoads DD (2019) Clinical laboratory tests used to aid in diagnosis of human prion disease. J Clin Microbiol 57(10):10\u20131128. https:\/\/doi.org\/10.1128\/jcm.00769-19","journal-title":"J Clin Microbiol"},{"issue":"2","key":"10754_CR10","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1212\/WNL.0000000000007745","volume":"93","author":"EV Minikel","year":"2019","unstructured":"Minikel EV, Vallabh SM, Orseth MC, Brandel J-P, Ha\u00efk S, Laplanche J-L et al (2019) Age at onset in genetic prion disease and the design of preventive clinical trials. Neurology 93(2):e125\u2013e134","journal-title":"Neurology"},{"issue":"21","key":"10754_CR11","doi-asserted-by":"crossref","first-page":"4959","DOI":"10.1242\/jcs.02609","volume":"118","author":"M Nunziante","year":"2005","unstructured":"Nunziante M, Kehler C, Maas E, Kassack MU, Groschup M, Sch\u00e4tzl HM (2005) Charged bipolar suramin derivatives induce aggregation of the prion protein at the cell surface and inhibit PrPSc replication. J Cell Sci 118(21):4959\u20134973","journal-title":"J Cell Sci"},{"issue":"12","key":"10754_CR12","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1002\/pro.3735","volume":"28","author":"PK Baral","year":"2019","unstructured":"Baral PK, Yin J, Aguzzi A, James MNG (2019) Transition of the prion protein from a structured cellular form (PrP(C)) to the infectious scrapie agent (PrP(Sc)). Protein Sci\u202f: Publ Protein Soc 28(12):2055\u20132063","journal-title":"Protein Sci : Publ Protein Soc"},{"issue":"1","key":"10754_CR13","doi-asserted-by":"crossref","first-page":"27867","DOI":"10.1038\/s41598-024-79217-1","volume":"14","author":"J Myskiw","year":"2024","unstructured":"Myskiw J, Bailey-Elkin BA, Avery K, Barria MA, Ritchie DL, Cohen ML et al (2024) Characterization of variably protease-sensitive prionopathy by capillary electrophoresis. Sci Rep 14(1):27867","journal-title":"Sci Rep"},{"issue":"7","key":"10754_CR14","doi-asserted-by":"crossref","first-page":"e209272","DOI":"10.1212\/WNL.0000000000209272","volume":"102","author":"E Benarroch","year":"2024","unstructured":"Benarroch E (2024) What are the roles of cellular prion protein in normal and pathologic conditions? Neurology 102(7):e209272","journal-title":"Neurology"},{"key":"10754_CR15","doi-asserted-by":"crossref","first-page":"1324702","DOI":"10.3389\/fnmol.2024.1324702","volume":"17","author":"F Liu","year":"2024","unstructured":"Liu F, L\u00fc W, Liu L (2024) New implications for prion diseases therapy and prophylaxis. Front Mol Neurosci 17:1324702","journal-title":"Front Mol Neurosci"},{"issue":"2","key":"10754_CR16","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.neures.2012.03.005","volume":"73","author":"J-K Jeong","year":"2012","unstructured":"Jeong J-K, Moon M-H, Bae B-C, Lee Y-J, Seol J-W, Kang H-S et al (2012) Autophagy induced by resveratrol prevents human prion protein-mediated neurotoxicity. Neurosci Res 73(2):99\u2013105","journal-title":"Neurosci Res"},{"key":"10754_CR17","doi-asserted-by":"crossref","first-page":"114923","DOI":"10.1016\/j.ejmech.2022.114923","volume":"245","author":"M Staderini","year":"2023","unstructured":"Staderini M, Vanni S, Baldeschi AC, Giachin G, Zattoni M, Celauro L et al (2023) Bifunctional carbazole derivatives for simultaneous therapy and fluorescence imaging in prion disease murine cell models. Eur J Med Chem 245:114923","journal-title":"Eur J Med Chem"},{"issue":"1","key":"10754_CR18","doi-asserted-by":"crossref","first-page":"e55282","DOI":"10.1371\/journal.pone.0055282","volume":"8","author":"JM McCarthy","year":"2013","unstructured":"McCarthy JM, Franke M, Resenberger UK, Waldron S, Simpson JC, Tatzelt J et al (2013) Anti-prion drug mPPIg5 inhibits PrPC conversion to PrPSc. PLoS ONE 8(1):e55282","journal-title":"PLoS ONE"},{"issue":"5","key":"10754_CR19","doi-asserted-by":"crossref","first-page":"470","DOI":"10.4161\/pri.21913","volume":"6","author":"F Koukouli","year":"2012","unstructured":"Koukouli F, Paspaltsis I, Salta E, Xanthopoulos K, Koini EN, Calogeropoulou T et al (2012) Inhibition of PrPSc formation in scrapie infected N2a cells by 5, 7, 8-trimethyl-3, 4-dihydro-2 H-1, 4-benzoxazine derivatives. Prion 6(5):470\u2013476","journal-title":"Prion"},{"issue":"11","key":"10754_CR20","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1016\/j.biomaterials.2011.01.017","volume":"32","author":"C Ryou","year":"2011","unstructured":"Ryou C, Titlow WB, Mays CE, Bae Y, Kim S (2011) The suppression of prion propagation using poly-L-lysine by targeting plasminogen that stimulates prion protein conversion. Biomaterials 32(11):3141\u20133149","journal-title":"Biomaterials"},{"issue":"3","key":"10754_CR21","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/j.1471-4159.2008.05628.x","volume":"107","author":"Y Iwamaru","year":"2008","unstructured":"Iwamaru Y, Shimizu Y, Imamura M, Murayama Y, Endo R, Tagawa Y et al (2008) Lactoferrin induces cell surface retention of prion protein and inhibits prion accumulation. J Neurochem 107(3):636\u2013646","journal-title":"J Neurochem"},{"issue":"4","key":"10754_CR22","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1080\/13550280701361516","volume":"13","author":"S-W Yun","year":"2007","unstructured":"Yun S-W, Ertmer A, Flechsig E, Gilch S, Riederer P, Gerlach M et al (2007) The tyrosine kinase inhibitor imatinib mesylate delays prion neuroinvasion by inhibiting prion propagation in the periphery. J Neurovirol 13(4):328\u2013337","journal-title":"J Neurovirol"},{"issue":"8","key":"10754_CR23","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/1439-7633(20020802)3:8<717::AID-CBIC717>3.0.CO;2-C","volume":"3","author":"D Proske","year":"2002","unstructured":"Proske D, Gilch S, Wopfner F, Sch\u00e4tzl HM, Winnacker EL, Famulok M (2002) Prion-protein-specific aptamer reduces PrPSc formation. ChemBioChem 3(8):717\u2013725","journal-title":"ChemBioChem"},{"issue":"42","key":"10754_CR24","doi-asserted-by":"crossref","first-page":"25901","DOI":"10.1039\/D1RA01891D","volume":"11","author":"PR Sirohi","year":"2021","unstructured":"Sirohi PR, Kumari A, Admane N, Somvanshi P, Grover A (2021) The polyphenolic phytoalexin polydatin inhibits amyloid aggregation of recombinant human prion protein. RSC Adv 11(42):25901\u201325911","journal-title":"RSC Adv"},{"key":"10754_CR25","doi-asserted-by":"crossref","unstructured":"M Waqas, HT Trinh, S Lee, D-h Kim, SY Lee, KK Choe, et al. (2018) Decrease of protease-resistant PrPSc level in ScN2a cells by polyornithine and polyhistidine","DOI":"10.4014\/jmb.1807.07045"},{"issue":"5","key":"10754_CR26","doi-asserted-by":"crossref","first-page":"103974","DOI":"10.1016\/j.drudis.2024.103974","volume":"29","author":"A Mukherjee","year":"2024","unstructured":"Mukherjee A, Biswas S, Roy I (2024) Immunotherapy: an emerging treatment option for neurodegenerative diseases. Drug Discov Today 29(5):103974","journal-title":"Drug Discov Today"},{"key":"10754_CR27","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1146\/annurev.neuro.31.060407.125529","volume":"31","author":"DL Brody","year":"2008","unstructured":"Brody DL, Holtzman DM (2008) Active and passive immunotherapy for neurodegenerative disorders. Annu Rev Neurosci 31:175\u2013193","journal-title":"Annu Rev Neurosci"},{"key":"10754_CR28","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.coph.2019.04.019","volume":"44","author":"G Forloni","year":"2019","unstructured":"Forloni G, Roiter I, Tagliavini F (2019) Clinical trials of prion disease therapeutics. Curr Opin Pharmacol 44:53\u201360","journal-title":"Curr Opin Pharmacol"},{"issue":"5","key":"10754_CR29","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.vaccine.2014.11.035","volume":"33","author":"F Go\u00f1i","year":"2015","unstructured":"Go\u00f1i F, Mathiason CK, Yim L, Wong K, Hayes-Klug J, Nalls A et al (2015) Mucosal immunization with an attenuated Salmonella vaccine partially protects white-tailed deer from chronic wasting disease. Vaccine 33(5):726\u2013733","journal-title":"Vaccine"},{"issue":"2","key":"10754_CR30","doi-asserted-by":"crossref","first-page":"66","DOI":"10.4161\/pri.4.2.12597","volume":"4","author":"C Carnaud","year":"2010","unstructured":"Carnaud C, Bachy V (2010) Cell-based immunotherapy of prion diseases by adoptive transfer of antigen-loaded dendritic cells or antigen-primed CD4+ T lymphocytes. Prion 4(2):66\u201371","journal-title":"Prion"},{"key":"10754_CR31","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/B978-0-444-63945-5.00005-2","volume":"153","author":"NA Mabbott","year":"2018","unstructured":"Mabbott NA, Alibhai JD, Manson J (2018) The role of the immune system in prion infection. Handb Clin Neurol 153:85\u2013107","journal-title":"Handb Clin Neurol"},{"issue":"1","key":"10754_CR32","doi-asserted-by":"crossref","first-page":"016002","DOI":"10.1117\/1.JMI.7.1.016002","volume":"7","author":"S Subramanian","year":"2020","unstructured":"Subramanian S, Rajamanickam K, Prakash JS, Ramachandran M (2020) Disease neuroimaging initiative fAs. study on structural atrophy changes and functional connectivity measures in Alzheimer\u2019s disease. J Med Imag 7(1):016002","journal-title":"J Med Imag"},{"issue":"6","key":"10754_CR33","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s43587-021-00070-2","volume":"1","author":"P Novak","year":"2021","unstructured":"Novak P, Kovacech B, Katina S, Schmidt R, Scheltens P, Kontsekova E et al (2021) ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer\u2019s disease. Nat Aging 1(6):521\u2013534","journal-title":"Nat Aging"},{"issue":"17","key":"10754_CR34","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1016\/j.vaccine.2014.01.027","volume":"32","author":"K Marciniuk","year":"2014","unstructured":"Marciniuk K, M\u00e4\u00e4tt\u00e4nen P, Taschuk R, Airey TD, Potter A, Cashman NR et al (2014) Development of a multivalent, PrPSc-specific prion vaccine through rational optimization of three disease-specific epitopes. Vaccine 32(17):1988\u20131997","journal-title":"Vaccine"},{"issue":"2","key":"10754_CR35","doi-asserted-by":"crossref","first-page":"83","DOI":"10.4161\/pri.1.2.4346","volume":"1","author":"AD Steele","year":"2007","unstructured":"Steele AD, Lindquist S, Aguzzi A (2007) The prion protein knockout mouse: a phenotype under challenge. Prion 1(2):83\u201393","journal-title":"Prion"},{"issue":"1","key":"10754_CR36","doi-asserted-by":"crossref","first-page":"9493","DOI":"10.1038\/s41598-022-13455-z","volume":"12","author":"M Reilly","year":"2022","unstructured":"Reilly M, Benilova I, Khalili-Shirazi A, Schmidt C, Ahmed P, Yip D et al (2022) A high-content neuron imaging assay demonstrates inhibition of prion disease-associated neurotoxicity by an anti-prion protein antibody. Sci Rep 12(1):9493","journal-title":"Sci Rep"},{"issue":"5976","key":"10754_CR37","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/310418a0","volume":"310","author":"PE Bendheim","year":"1984","unstructured":"Bendheim PE, Barry RA, DeArmond SJ, Stites DP, Prusiner SB (1984) Antibodies to a scrapie prion protein. Nature 310(5976):418\u2013421","journal-title":"Nature"},{"issue":"50","key":"10754_CR38","doi-asserted-by":"crossref","first-page":"7737","DOI":"10.1016\/j.vaccine.2018.10.057","volume":"36","author":"ME Wood","year":"2018","unstructured":"Wood ME, Griebel P, Huizenga ML, Lockwood S, Hansen C, Potter A et al (2018) Accelerated onset of chronic wasting disease in elk (Cervus canadensis) vaccinated with a PrPSc-specific vaccine and housed in a prion contaminated environment. Vaccine 36(50):7737\u20137743","journal-title":"Vaccine"},{"issue":"1","key":"10754_CR39","doi-asserted-by":"crossref","first-page":"51","DOI":"10.4161\/pri.27962","volume":"8","author":"R Taschuk","year":"2014","unstructured":"Taschuk R, Marciniuk K, M\u00e4\u00e4tt\u00e4nen P, Madampage C, Hedlin P, Potter A et al (2014) Safety, specificity and immunogenicity of a PrPSc-specific prion vaccine based on the YYR disease specific epitope. Prion 8(1):51\u201359","journal-title":"Prion"},{"issue":"3","key":"10754_CR40","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1099\/vir.0.013417-0","volume":"91","author":"V Bachy","year":"2010","unstructured":"Bachy V, Ballerini C, Gourdain P, Prignon A, Iken S, Antoine N et al (2010) Mouse vaccination with dendritic cells loaded with prion protein peptides overcomes tolerance and delays scrapie. J Gen Virol 91(3):809\u2013820","journal-title":"J Gen Virol"},{"issue":"4","key":"10754_CR41","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S1474-4422(22)00082-5","volume":"21","author":"S Mead","year":"2022","unstructured":"Mead S, Khalili-Shirazi A, Potter C, Mok T, Nihat A, Hyare H et al (2022) Prion protein monoclonal antibody (PRN100) therapy for Creutzfeldt-Jakob disease: evaluation of a first-in-human treatment programme. Lancet Neurol 21(4):342\u2013354","journal-title":"Lancet Neurol"},{"issue":"12","key":"10754_CR42","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1172\/JCI29236","volume":"116","author":"A Pfeifer","year":"2006","unstructured":"Pfeifer A, Eigenbrod S, Al-Khadra S, Hofmann A, Mitteregger G, Moser M et al (2006) Lentivector-mediated RNAi efficiently suppresses prion protein and prolongs survival of scrapie-infected mice. J Clin Investig 116(12):3204\u20133210","journal-title":"J Clin Investig"},{"issue":"3","key":"10754_CR43","doi-asserted-by":"crossref","first-page":"121","DOI":"10.4161\/pri.3.3.9289","volume":"3","author":"MD White","year":"2009","unstructured":"White MD, Mallucci GR (2009) Therapy for prion diseases: Insights from the use of RNA interference. Prion 3(3):121\u2013128","journal-title":"Prion"},{"issue":"2","key":"10754_CR44","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s12192-021-01191-8","volume":"26","author":"J Abrams","year":"2021","unstructured":"Abrams J, Arhar T, Mok SA, Taylor IR, Kampmann M, Gestwicki JE (2021) Functional genomics screen identifies proteostasis targets that modulate prion protein (PrP) stability. Cell Stress Chaperones 26(2):443\u2013452","journal-title":"Cell Stress Chaperones"},{"issue":"21","key":"10754_CR45","doi-asserted-by":"crossref","first-page":"15919","DOI":"10.3390\/ijms242115919","volume":"24","author":"X Zheng","year":"2023","unstructured":"Zheng X, Liu K, Xie Q, Xin H, Chen W, Lin S, Feng D, Zhu T (2023) PHB2 Alleviates neurotoxicity of prion peptide PrP106\u2013126 via PINK1\/Parkin-dependent mitophagy. Int J Mol Sci 24(21):15919","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10754_CR46","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13567-022-01075-4","volume":"53","author":"A Rau","year":"2022","unstructured":"Rau A, Passet B, Castille J, Daniel-Carlier N, Asset A, Lecardonnel J et al (2022) Potential genetic robustness of Prnp and Sprn double knockout mouse embryos towards ShRNA-lentiviral inoculation. Vet Res 53(1):54","journal-title":"Vet Res"},{"issue":"8","key":"10754_CR47","doi-asserted-by":"crossref","first-page":"949","DOI":"10.3390\/biom14080949","volume":"14","author":"AM Caramiello","year":"2024","unstructured":"Caramiello AM, Pirota V (2024) Novel therapeutic horizons: SNCA targeting in parkinson\u2019s disease. Biomolecules 14(8):949","journal-title":"Biomolecules"},{"key":"10754_CR48","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.conb.2021.07.010","volume":"72","author":"M Carta","year":"2022","unstructured":"Carta M, Aguzzi A (2022) Molecular foundations of prion strain diversity. Curr Opin Neurobiol 72:22\u201331","journal-title":"Curr Opin Neurobiol"},{"key":"10754_CR49","doi-asserted-by":"crossref","unstructured":"Nazor Friberg K, Hung G, Wancewicz E, Giles K, Black C, Freier S, et al. (2012) intracerebral infusion of antisense Oligonucleotides Into Prion-infected Mice. Mol Ther Nucl Acids 1","DOI":"10.1038\/mtna.2011.6"},{"issue":"19","key":"10754_CR50","doi-asserted-by":"crossref","first-page":"10615","DOI":"10.1093\/nar\/gkaa616","volume":"48","author":"EV Minikel","year":"2020","unstructured":"Minikel EV, Zhao HT, Le J, O\u2019Moore J, Pitstick R, Graffam S et al (2020) Prion protein lowering is a disease-modifying therapy across prion disease stages, strains and endpoints. Nucleic Acids Res 48(19):10615\u201310631","journal-title":"Nucleic Acids Res"},{"key":"10754_CR51","doi-asserted-by":"crossref","unstructured":"An M, Davis JR, Levy JM, Serack FE, Harvey JW, Brauer PP, et al. (2025) In vivo base editing extends lifespan of a humanized mouse model of prion disease. Nat Med 1\u201310","DOI":"10.1038\/s41591-024-03466-w"},{"key":"10754_CR52","doi-asserted-by":"publisher","DOI":"10.1101\/2025.03.05.636713","author":"S-W Chou","year":"2025","unstructured":"Chou S-W, Mortberg MA, Marlen K, Ojala DS, Parman T, Howard M et al (2025) Zinc finger repressors mediate widespread PRNP lowering in the nonhuman primate brain and profoundly extend survival in prion disease mice. bioRxiv. https:\/\/doi.org\/10.1101\/2025.03.05.636713","journal-title":"bioRxiv"},{"issue":"16","key":"10754_CR53","doi-asserted-by":"crossref","first-page":"e131175","DOI":"10.1172\/jci.insight.131175","volume":"4","author":"GJ Raymond","year":"2019","unstructured":"Raymond GJ, Zhao HT, Race B, Raymond LD, Williams K, Swayze EE et al (2019) Antisense oligonucleotides extend survival of prion-infected mice. JCI insight 4(16):e131175","journal-title":"JCI insight"},{"issue":"4","key":"10754_CR54","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.cell.2022.12.032","volume":"186","author":"DM Wilson","year":"2023","unstructured":"Wilson DM, Cookson MR, Van Den Bosch L, Zetterberg H, Holtzman DM, Dewachter I (2023) Hallmarks of neurodegenerative diseases. Cell 186(4):693\u2013714","journal-title":"Cell"},{"issue":"22","key":"10754_CR55","doi-asserted-by":"crossref","first-page":"14498","DOI":"10.3390\/ijms232214498","volume":"23","author":"A Ochneva","year":"2022","unstructured":"Ochneva A, Zorkina Y, Abramova O, Pavlova O, Ushakova V, Morozova A et al (2022) Protein misfolding and aggregation in the brain: common pathogenetic pathways in neurodegenerative and mental disorders. Int J Mol Sci 23(22):14498","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10754_CR56","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00441-021-03573-x","volume":"392","author":"E Uliassi","year":"2023","unstructured":"Uliassi E, Nikolic L, Bolognesi ML, Legname G (2023) Therapeutic strategies for identifying small molecules against prion diseases. Cell Tissue Res 392(1):337\u2013347","journal-title":"Cell Tissue Res"},{"key":"10754_CR57","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.msec.2016.09.049","volume":"70","author":"SK Metkar","year":"2017","unstructured":"Metkar SK, Girigoswami A, Murugesan R, Girigoswami K (2017) In vitro and in vivo insulin amyloid degradation mediated by Serratiopeptidase. Mater Sci Eng C 70:728\u2013735","journal-title":"Mater Sci Eng C"},{"issue":"2","key":"10754_CR58","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jab.2017.01.003","volume":"15","author":"SK Metkar","year":"2017","unstructured":"Metkar SK, Girigoswami A, Murugesan R, Girigoswami K (2017) Lumbrokinase for degradation and reduction of amyloid fibrils associated with amyloidosis. J Appl Biomed 15(2):96\u2013104","journal-title":"J Appl Biomed"},{"issue":"9","key":"10754_CR59","doi-asserted-by":"crossref","first-page":"723","DOI":"10.2174\/1871527318666191021150002","volume":"18","author":"SK Metkar","year":"2019","unstructured":"Metkar SK, Ghosh S, Girigoswami A, Girigoswami K (2019) The potential of serratiopetidase and lumbrokinase for the degradation of prion peptide 106\u2013126-an in vitro and in silico perspective. CNS Neurol Disord-Drug Target-CNS Neurol Disord 18(9):723\u2013731","journal-title":"CNS Neurol Disord-Drug Target-CNS Neurol Disord"},{"key":"10754_CR60","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ijbiomac.2020.06.256","volume":"163","author":"SK Metkar","year":"2020","unstructured":"Metkar SK, Girigoswami A, Vijayashree R, Girigoswami K (2020) Attenuation of subcutaneous insulin induced amyloid mass in vivo using Lumbrokinase and Serratiopeptidase. Int J Biol Macromol 163:128\u2013134","journal-title":"Int J Biol Macromol"},{"issue":"2","key":"10754_CR61","first-page":"1","volume":"134","author":"SK Metkar","year":"2022","unstructured":"Metkar SK, Girigoswami A, Bondage DD, Shinde UG, Girigoswami K (2022) The potential of lumbrokinase and serratiopeptidase for the degradation of A\u03b2 1\u201342 peptide\u2013an in vitro and in silico approach. Int J Neurosci 134(2):1\u201312","journal-title":"Int J Neurosci"},{"issue":"6","key":"10754_CR62","first-page":"797","volume":"12","author":"SK Metkar","year":"2024","unstructured":"Metkar SK, Udayakumar S, Girigoswami A, Girigoswami K (2024) Natural serine proteases and their applications in combating amyloid formation. ADMET and DMPK 12(6):797\u2013820","journal-title":"ADMET and DMPK"},{"key":"10754_CR63","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.msec.2019.03.086","volume":"101","author":"A Girigoswami","year":"2019","unstructured":"Girigoswami A, Ramalakshmi M, Akhtar N, Metkar SK, Girigoswami K (2019) ZnO Nanoflower petals mediated amyloid degradation-An in vitro electrokinetic potential approach. Mater Sci Eng, C 101:169\u2013178","journal-title":"Mater Sci Eng, C"},{"issue":"6","key":"10754_CR64","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1007\/s40495-022-00307-7","volume":"8","author":"K Harini","year":"2022","unstructured":"Harini K, Girigoswami K, Anand AV, Pallavi P, Gowtham P, Elboughdiri N et al (2022) Nano-mediated strategies for metal ion\u2013induced neurodegenerative disorders: focus on Alzheimer\u2019s and Parkinson\u2019s diseases. Curr Pharmacol Rep 8(6):450\u2013463","journal-title":"Curr Pharmacol Rep"},{"key":"10754_CR65","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s12640-018-9978-z","volume":"35","author":"V Manigandan","year":"2019","unstructured":"Manigandan V, Nataraj J, Karthik R, Manivasagam T, Saravanan R, Thenmozhi AJ et al (2019) Low molecular weight sulfated chitosan: neuroprotective effect on rotenone-induced in vitro Parkinson\u2019s disease. Neurotox Res 35:505\u2013515","journal-title":"Neurotox Res"},{"issue":"1","key":"10754_CR66","doi-asserted-by":"crossref","first-page":"11399","DOI":"10.1038\/s41598-023-38172-z","volume":"13","author":"MS Selim","year":"2023","unstructured":"Selim MS, Mohamed SS, Asker MS, Ibrahim AY, El-Newary SA, El Awady ME (2023) Characterization and in-vitro Alzheimer\u2019s properties of exopolysaccharide from Bacillus maritimus MSM1. Sci Rep 13(1):11399","journal-title":"Sci Rep"},{"issue":"1","key":"10754_CR67","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1080\/19336896.2022.2153551","volume":"16","author":"KH Shim","year":"2022","unstructured":"Shim KH, Sharma N, An SSA (2022) Prion therapeutics: Lessons from the past. Prion 16(1):265\u2013294","journal-title":"Prion"},{"issue":"33","key":"10754_CR68","doi-asserted-by":"crossref","first-page":"35223","DOI":"10.1021\/acsomega.4c01774","volume":"9","author":"O Ozceylan","year":"2024","unstructured":"Ozceylan O, Sezgin-Bayindir Z (2024) Current overview on the use of nanosized drug delivery systems in the treatment of neurodegenerative diseases. ACS Omega 9(33):35223\u201335242","journal-title":"ACS Omega"},{"issue":"2","key":"10754_CR69","doi-asserted-by":"crossref","first-page":"250","DOI":"10.5858\/2001-125-0250-CR","volume":"125","author":"DP Steensma","year":"2001","unstructured":"Steensma DP (2001) \u201cCongo\u201d red: out of Africa? Arch Pathol Lab Med 125(2):250\u2013252","journal-title":"Arch Pathol Lab Med"},{"key":"10754_CR70","unstructured":"Jalandoni-Buan AC, Decena-Soliven ALA, Cao EP, Barraquio VL, Barraquio WL 2010. Characterization and identification of Congo red decolorizing bacteria from monocultures and consortia. Philippine J Sci.;139(1)."},{"key":"10754_CR71","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.ijid.2020.03.031","volume":"93","author":"E Shim","year":"2020","unstructured":"Shim E, Tariq A, Choi W, Lee Y, Chowell G (2020) Transmission potential and severity of COVID-19 in South Korea. Int J Infect Dis 93:339\u2013344","journal-title":"Int J Infect Dis"},{"issue":"3","key":"10754_CR72","doi-asserted-by":"crossref","first-page":"e0229796","DOI":"10.1371\/journal.pone.0229796","volume":"15","author":"JE Dorweiler","year":"2020","unstructured":"Dorweiler JE, Obaoye JO, Oddo MJ, Shilati FM, Scheidemantle GM, Coleman TJ et al (2020) DMSO-mediated curing of several yeast prion variants involves Hsp104 expression and protein solubilization, and is decreased in several autophagy related gene (atg) mutants. PLoS ONE 15(3):e0229796","journal-title":"PLoS ONE"},{"key":"10754_CR73","doi-asserted-by":"crossref","unstructured":"Jacob SW, de la Torre JC 2015. Dimethyl sulfoxide (DMSO) in trauma and disease: CRC press;.","DOI":"10.1201\/b18275"},{"issue":"1","key":"10754_CR74","doi-asserted-by":"crossref","first-page":"2176280","DOI":"10.1080\/23311932.2023.2176280","volume":"9","author":"CG Awuchi","year":"2023","unstructured":"Awuchi CG (2023) HACCP, quality, and food safety management in food and agricultural systems. Cogent Food Agric 9(1):2176280","journal-title":"Cogent Food Agric"},{"issue":"4","key":"10754_CR75","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1073\/pnas.79.4.1158","volume":"79","author":"H Murakami","year":"1982","unstructured":"Murakami H, Masui H, Sato GH, Sueoka N, Chow TP, Kano-Sueoka T (1982) Growth of hybridoma cells in serum-free medium: ethanolamine is an essential component. Proc Natl Acad Sci 79(4):1158\u20131162","journal-title":"Proc Natl Acad Sci"},{"issue":"21","key":"10754_CR76","doi-asserted-by":"crossref","first-page":"11742","DOI":"10.3390\/ijms222111742","volume":"22","author":"K Uchiyama","year":"2021","unstructured":"Uchiyama K, Hara H, Chida J, Pasiana AD, Imamura M, Mori T et al (2021) Ethanolamine is a new anti-prion compound. Int J Mol Sci 22(21):11742","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10754_CR77","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1099\/jgv.0.001262","volume":"100","author":"K Qin","year":"2019","unstructured":"Qin K, Zhao L, Solanki A, Busch C, Mastrianni J (2019) Anle138b prevents PrP plaque accumulation in Tg (PrP-A116V) mice but does not mitigate clinical disease. J Gen Virol 100(6):1027\u20131037","journal-title":"J Gen Virol"},{"issue":"2","key":"10754_CR78","doi-asserted-by":"crossref","first-page":"e01672","DOI":"10.1128\/jvi.01672-22","volume":"97","author":"SM Vallabh","year":"2023","unstructured":"Vallabh SM, Zou D, Pitstick R, O\u2019Moore J, Peters J, Silvius D et al (2023) Therapeutic trial of anle138b in mouse models of genetic prion disease. J Virol 97(2):e01672-e1722","journal-title":"J Virol"},{"key":"10754_CR79","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s00401-013-1114-9","volume":"125","author":"J Wagner","year":"2013","unstructured":"Wagner J, Ryazanov S, Leonov A, Levin J, Shi S, Schmidt F et al (2013) Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson\u2019s disease. Acta Neuropathol 125:795\u2013813","journal-title":"Acta Neuropathol"},{"issue":"9","key":"10754_CR80","doi-asserted-by":"crossref","first-page":"e2010213118","DOI":"10.1073\/pnas.2010213118","volume":"118","author":"R Petrosyan","year":"2021","unstructured":"Petrosyan R, Patra S, Rezajooei N, Garen CR, Woodside MT (2021) Unfolded and intermediate states of PrP play a key role in the mechanism of action of an antiprion chaperone. Proc Natl Acad Sci 118(9):e2010213118","journal-title":"Proc Natl Acad Sci"},{"issue":"5","key":"10754_CR81","doi-asserted-by":"crossref","first-page":"e13197","DOI":"10.1111\/bpa.13197","volume":"33","author":"M Shijo","year":"2023","unstructured":"Shijo M, Yoshimura M, Omae T, Hashimoto G, Mizoguchi T, Kuwashiro T et al (2023) Altered properties of amyloidogenic prion protein in genetic Creutzfeldt-Jakob disease with PRNP V180I mutation in response to pentosan polysulfate. Brain Pathol 33(5):e13197","journal-title":"Brain Pathol"},{"key":"10754_CR82","doi-asserted-by":"crossref","first-page":"113867","DOI":"10.1016\/j.bcp.2020.113867","volume":"175","author":"M Asperti","year":"2020","unstructured":"Asperti M, Denardo A, Gryzik M, Castagna A, Girelli D, Naggi A et al (2020) Pentosan polysulfate to control hepcidin expression in vitro and in vivo. Biochem Pharmacol 175:113867","journal-title":"Biochem Pharmacol"},{"key":"10754_CR83","doi-asserted-by":"crossref","unstructured":"Cavaliere P, Torrent J, Prigent S, Granata V, Pauwels K, Pastore A, et al. 2013 Binding of methylene blue to a surface cleft inhibits the oligomerization and fibrillization of prion protein. Biochimica et Biophysica Acta (BBA)-Mol Basis Dis.;1832(1):20\u20138.","DOI":"10.1016\/j.bbadis.2012.09.005"},{"key":"10754_CR84","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.9719","volume":"8","author":"G Musteikyte","year":"2020","unstructured":"Musteikyte G, Ziaunys M, Smirnovas V (2020) Methylene blue inhibits nucleation and elongation of SOD1 amyloid fibrils. PeerJ 8:e9719","journal-title":"PeerJ"},{"issue":"8","key":"10754_CR85","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.arcmed.2021.06.002","volume":"52","author":"B Pineda","year":"2021","unstructured":"Pineda B (2021) Quinacrine, an old drug with potentially usefull in the treatment for COVID-19. Arch Med Res 52(8):858","journal-title":"Arch Med Res"},{"issue":"1","key":"10754_CR86","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3390\/v13010121","volume":"13","author":"M Salas Rojas","year":"2021","unstructured":"Salas Rojas M, Silva Garcia R, Bini E, P\u00e9rez de la Cruz V, Le\u00f3n Contreras JC, Hern\u00e1ndez Pando R et al (2021) Quinacrine, an antimalarial drug with strong activity inhibiting SARS-CoV-2 viral replication in vitro. Viruses 13(1):121","journal-title":"Viruses"},{"issue":"6","key":"10754_CR87","doi-asserted-by":"crossref","first-page":"707","DOI":"10.4269\/ajtmh.1951.s1-31.707","volume":"31","author":"PE Thompson","year":"1951","unstructured":"Thompson PE, Reinertson J (1951) Chemotherapy of Amebic Hepatitis in Hamsters with Emetine, Chloroquine, Amodiaquin (Camoquin), Quinaerine and Other Drugs. Am J Trop Med 31(6):707\u2013717","journal-title":"Am J Trop Med"},{"issue":"4","key":"10754_CR88","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S1474-4422(22)00083-7","volume":"21","author":"I Zerr","year":"2022","unstructured":"Zerr I (2022) Investigating new treatments for Creutzfeldt-Jakob disease. The Lancet Neurology 21(4):299\u2013300","journal-title":"The Lancet Neurology"},{"issue":"15","key":"10754_CR89","doi-asserted-by":"crossref","first-page":"8462","DOI":"10.1128\/JVI.77.15.8462-8469.2003","volume":"77","author":"A Barret","year":"2003","unstructured":"Barret A, Tagliavini F, Forloni G, Bate C, Salmona M, Colombo L et al (2003) Evaluation of quinacrine treatment for prion diseases. J Virol 77(15):8462\u20138469","journal-title":"J Virol"},{"issue":"4","key":"10754_CR90","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/S1474-4422(09)70049-3","volume":"8","author":"J Collinge","year":"2009","unstructured":"Collinge J, Gorham M, Hudson F, Kennedy A, Keogh G, Pal S et al (2009) Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial. The Lancet Neurology 8(4):334\u2013344","journal-title":"The Lancet Neurology"},{"issue":"11","key":"10754_CR91","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000673","volume":"5","author":"S Ghaemmaghami","year":"2009","unstructured":"Ghaemmaghami S, Ahn M, Lessard P, Giles K, Legname G, DeArmond SJ et al (2009) Continuous quinacrine treatment results in the formation of drug-resistant prions. PLoS Pathog 5(11):e1000673","journal-title":"PLoS Pathog"},{"issue":"23","key":"10754_CR92","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1212\/WNL.0b013e3182a9f3b4","volume":"81","author":"MD Geschwind","year":"2013","unstructured":"Geschwind MD, Kuo AL, Wong KS, Haman A, Devereux G, Raudabaugh BJ et al (2013) Quinacrine treatment trial for sporadic Creutzfeldt-Jakob disease. Neurology 81(23):2015\u20132023","journal-title":"Neurology"},{"key":"10754_CR93","unstructured":"Boustany R, Makoukji J, Saab S, Maalouf K, Makhoul N, Carmona A 2021. Sex-Specific Gene Expression in Flupirtine-Treated Cln3\u03b4ex7\/8 Mouse Brain. Biochem Pharmacol.;10."},{"issue":"21","key":"10754_CR94","doi-asserted-by":"crossref","first-page":"8181","DOI":"10.1002\/ange.201916630","volume":"132","author":"A Espargar\u00f3","year":"2020","unstructured":"Espargar\u00f3 A, Llabr\u00e9s S, Saupe SJ, Curutchet C, Luque FJ, Sabat\u00e9 R (2020) On the binding of Congo Red to amyloid fibrils. Angew Chem 132(21):8181\u20138184","journal-title":"Angew Chem"},{"issue":"13","key":"10754_CR95","doi-asserted-by":"crossref","first-page":"8998","DOI":"10.1021\/acs.jmedchem.2c00205","volume":"65","author":"A Colini Baldeschi","year":"2022","unstructured":"Colini Baldeschi A, Zattoni M, Vanni S, Nikolic L, Ferracin C, La Sala G et al (2022) Innovative non-PrP-targeted drug strategy designed to enhance prion clearance. J Med Chem 65(13):8998\u20139010","journal-title":"J Med Chem"},{"key":"10754_CR96","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104021","author":"J Levin","year":"2022","unstructured":"Levin J, Sing N, Melbourne S, Morgan A, Mariner C, Spillantini MG, Wegrzynowicz M, Dalley JW, Langer S, Ryazanov S, Leonov A (2022) Safety, tolerability and pharmacokinetics of the oligomer modulator anle138b with exposure levels sufficient for therapeutic efficacy in a murine Parkinson model: A randomised, double-blind, placebo-controlled phase 1a trial. EBioMed. https:\/\/doi.org\/10.1016\/j.ebiom.2022.104021","journal-title":"EBioMed"},{"key":"10754_CR97","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.neures.2021.01.004","volume":"171","author":"T Fuse","year":"2021","unstructured":"Fuse T, Nakagaki T, Homma T, Tange H, Yamaguchi N, Atarashi R et al (2021) Dextran sulphate inhibits an association of prions with plasma membrane at the early phase of infection. Neurosci Res 171:34\u201340","journal-title":"Neurosci Res"},{"issue":"1","key":"10754_CR98","doi-asserted-by":"crossref","first-page":"7923","DOI":"10.1038\/s41598-022-12049-z","volume":"12","author":"H Takatsuki","year":"2022","unstructured":"Takatsuki H, Imamura M, Mori T, Atarashi R (2022) Pentosan polysulfate induces low-level persistent prion infection keeping measurable seeding activity without PrP-res detection in Fukuoka-1 infected cell cultures. Sci Rep 12(1):7923","journal-title":"Sci Rep"},{"issue":"5","key":"10754_CR99","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1212\/01.WNL.0000113764.35026.EF","volume":"62","author":"M Otto","year":"2004","unstructured":"Otto M, Cepek L, Ratzka P, Doehlinger S, Boekhoff I, Wiltfang J et al (2004) Efficacy of flupirtine on cognitive function in patients with CJD: A double-blind study. Neurology 62(5):714\u2013718","journal-title":"Neurology"},{"issue":"4","key":"10754_CR100","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3390\/pharmaceutics10040281","volume":"10","author":"MA Patil","year":"2018","unstructured":"Patil MA, Matter BA, Raol YH, Bourne DW, Kelley RA, Kompella UB (2018) Brain distribution and metabolism of flupirtine, a nonopioid analgesic drug with antiseizure effects, in neonatal rats. Pharmaceutics 10(4):281","journal-title":"Pharmaceutics"},{"issue":"1","key":"10754_CR101","doi-asserted-by":"crossref","first-page":"93","DOI":"10.5607\/en.2020.29.1.93","volume":"29","author":"JW Hyeon","year":"2020","unstructured":"Hyeon JW, Noh R, Choi J, Lee SM, Lee YS, An SSA et al (2020) BMD42-2910, a novel benzoxazole derivative, shows a potent anti-prion activity and prolongs the mean survival in an animal model of prion disease. Exp Neurobiol 29(1):93","journal-title":"Exp Neurobiol"},{"issue":"1","key":"10754_CR102","doi-asserted-by":"crossref","first-page":"12043","DOI":"10.1038\/s41598-021-91563-y","volume":"11","author":"S Park","year":"2021","unstructured":"Park S, Kim HY, Oh H-A, Shin J, Park IW, Yoon S et al (2021) Quinacrine directly dissociates amyloid plaques in the brain of 5XFAD transgenic mouse model of Alzheimer\u2019s disease. Sci Rep 11(1):12043","journal-title":"Sci Rep"},{"key":"10754_CR103","doi-asserted-by":"crossref","unstructured":"Walsh DJ, Rees JR, Mehra S, Bourkas ME, Kaczmarczyk L, Stuart E, et al. Anti-prion drugs do not improve survival in knock-in models of inherited prion disease. bioRxiv. 2023:2023.09. 28.559951.","DOI":"10.1101\/2023.09.28.559951"},{"issue":"2","key":"10754_CR104","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S1474-4422(13)70307-7","volume":"13","author":"S Ha\u00efk","year":"2014","unstructured":"Ha\u00efk S, Marcon G, Mallet A, Tettamanti M, Welaratne A, Giaccone G et al (2014) Doxycycline in Creutzfeldt-Jakob disease: a phase 2, randomised, double-blind, placebo-controlled trial. The Lancet Neurol 13(2):150\u2013158","journal-title":"The Lancet Neurol"},{"key":"10754_CR105","doi-asserted-by":"crossref","first-page":"134814","DOI":"10.1016\/j.ijbiomac.2024.134814","volume":"279","author":"S Udayakumar","year":"2024","unstructured":"Udayakumar S, Metkar SK, Girigoswami A, Deepika B, Janani G, Kanakaraj L et al (2024) Exploring the amyloid degradation potential of nanoformulated carrageenan-bridging in vitro and in vivo perspectives. Int J Biol Macromol 279:134814","journal-title":"Int J Biol Macromol"},{"issue":"4","key":"10754_CR106","doi-asserted-by":"crossref","first-page":"23","DOI":"10.53388\/TMR20240822001","volume":"10","author":"A Girigoswami","year":"2025","unstructured":"Girigoswami A, Ghosh M, Girigoswami K (2025) World scenario of earthworms\u2019 prowess as a remedy to a spectrum of diseases\u2013a glimpse on related nanoformulations. Tradit Med Res 10(4):23","journal-title":"Tradit Med Res"},{"issue":"2","key":"10754_CR107","doi-asserted-by":"crossref","first-page":"4695","DOI":"10.1111\/ejn.15324","volume":"54","author":"D Chetty","year":"2021","unstructured":"Chetty D, Abrahams S, Van Coller R, Carr J, Kenyon C, Bardien S (2021) Movement of prion-like \u03b1-synuclein along the gut\u2013brain axis in Parkinson\u2019s disease: A potential target of curcumin treatment. Eur J Neurosci 54(2):4695\u20134711","journal-title":"Eur J Neurosci"},{"issue":"14","key":"10754_CR108","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1021\/acschemneuro.0c00218","volume":"11","author":"D-H Zhou","year":"2020","unstructured":"Zhou D-H, Wang J, Xiao K, Wu Y-Z, Maimaitiming A, Hu C et al (2020) Stilbene compounds inhibit the replications of various strains of prions in the levels of cell culture, PMCA, and RT-QuIC possibly via molecular binding. ACS Chem Neurosci 11(14):2117\u20132128","journal-title":"ACS Chem Neurosci"},{"key":"10754_CR109","doi-asserted-by":"publisher","unstructured":"Balasubramanian D, Girigoswami A, Girigoswami K. Nano resveratrol and its anticancer activity. CURRENT APPLIED SCIENCE AND TECHNOLOGY. 2023:https:\/\/doi.org\/10.55003\/cast. 2022.03. 23.010 (16 pages)-10.\/cast. 2022.03. 23.010 (16 pages).","DOI":"10.55003\/cast"},{"key":"10754_CR110","first-page":"1","volume":"18","author":"Y Hou","year":"2021","unstructured":"Hou Y, Luan J, Huang T, Deng T, Li X, Xiao Z et al (2021) Tauroursodeoxycholic acid alleviates secondary injury in spinal cord injury mice by reducing oxidative stress, apoptosis, and inflammatory response. J Neuroinflammation 18:1\u201313","journal-title":"J Neuroinflammation"},{"key":"10754_CR111","doi-asserted-by":"crossref","first-page":"819571","DOI":"10.3389\/fcell.2022.819571","volume":"10","author":"D Lumkwana","year":"2022","unstructured":"Lumkwana D, Peddie C, Kriel J, Michie L, Heathcote N, Collinson L et al (2022) Investigating the role of spermidine in a model system of alzheimer\u2019s disease using correlative microscopy and super-resolution techniques. Frontiers in Cell and Dev Biol 10:819571","journal-title":"Frontiers in Cell and Dev Biol"},{"key":"10754_CR112","doi-asserted-by":"crossref","first-page":"765398","DOI":"10.3389\/fmicb.2021.765398","volume":"12","author":"G Tang","year":"2021","unstructured":"Tang G, Xia H, Liang J, Ma Z, Liu W (2021) Spermidine is critical for growth, development, environmental adaptation, and virulence in Fusarium graminearum. Front Microbiol 12:765398","journal-title":"Front Microbiol"},{"issue":"4","key":"10754_CR113","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.bbrc.2007.11.074","volume":"365","author":"M Kanapathipillai","year":"2008","unstructured":"Kanapathipillai M, Ku SH, Girigoswami K, Park CB (2008) Small stress molecules inhibit aggregation and neurotoxicity of prion peptide 106\u2013126. Biochem Biophys Res Commun 365(4):808\u2013813","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"10754_CR114","doi-asserted-by":"crossref","first-page":"182","DOI":"10.3390\/ijms24010182","volume":"24","author":"S Lee","year":"2022","unstructured":"Lee S, Lee H, Kim J, Kim JH, Gao EM, Lee Y et al (2022) The effect of Curcuma phaeocaulis Valeton (Zingiberaceae) extract on prion propagation in cell-based and animal models. Int J Mol Sci 24(1):182","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10754_CR115","doi-asserted-by":"crossref","first-page":"5444","DOI":"10.1038\/s41598-025-89317-1","volume":"15","author":"K Teruya","year":"2025","unstructured":"Teruya K, Oguma A, Okuda M, Iwabuchi S, Konno H, Arai H et al (2025) Therapeutic effect of curcumin derivative GT863 on prion-infected mice. Sci Rep 15(1):5444","journal-title":"Sci Rep"},{"issue":"17","key":"10754_CR116","doi-asserted-by":"crossref","first-page":"4034","DOI":"10.3390\/molecules29174034","volume":"29","author":"J Kim","year":"2024","unstructured":"Kim J, Lee H, Kim HM, Kim JH, Byun S, Lee S et al (2024) Isolation of Anti-Prion Compounds from Curcuma phaeocaulis Valeton Extract. Molecules 29(17):4034","journal-title":"Molecules"},{"issue":"33","key":"10754_CR117","first-page":"729","volume":"4","author":"K Xiao","year":"2022","unstructured":"Xiao K, Shi Q, Chen C, Zhou W, Gao C, Gao L et al (2022) Establishment of a special platform for the research of prion and the diagnosis of human prion disease\u2014China\u2019s studies. China CDC Weekly 4(33):729","journal-title":"China CDC Weekly"},{"issue":"10","key":"10754_CR118","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1021\/acschemneuro.9b00341","volume":"10","author":"A Maimaitiming","year":"2019","unstructured":"Maimaitiming A, Xiao K, Hu C, Chen J, Yang X-H, Zhou D-H et al (2019) Aberrant decrease of the endogenous SIRT3 and increases of acetylated proteins in scrapie-infected cell line SMB-S15 and in the brains of experimental mice. ACS Chem Neurosci 10(10):4293\u20134302","journal-title":"ACS Chem Neurosci"},{"issue":"12","key":"10754_CR119","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.3390\/ijms21124274","volume":"21","author":"T-K Ahn","year":"2020","unstructured":"Ahn T-K, Kim K-T, Joshi HP, Park KH, Kyung JW, Choi U-Y et al (2020) Therapeutic potential of tauroursodeoxycholic acid for the treatment of osteoporosis. Int J Mol Sci 21(12):4274","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10754_CR120","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1600-079X.2012.00980.x","volume":"53","author":"JK Jeong","year":"2012","unstructured":"Jeong JK, Moon MH, Lee YJ, Seol JW, Park SY (2012) Melatonin-induced autophagy protects against human prion protein-mediated neurotoxicity. J Pineal Res 53(2):138\u2013146","journal-title":"J Pineal Res"},{"issue":"11","key":"10754_CR121","doi-asserted-by":"crossref","first-page":"11139","DOI":"10.18632\/aging.103328","volume":"12","author":"X Zhang","year":"2020","unstructured":"Zhang X, Zhao D, Wu W, Shah SZA, Lai M, Yang D et al (2020) Melatonin regulates mitochondrial dynamics and alleviates neuron damage in prion diseases. Aging (Albany NY) 12(11):11139","journal-title":"Aging (Albany NY)"},{"key":"10754_CR122","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116391","volume":"46","author":"R Kunitomi","year":"2021","unstructured":"Kunitomi R, Pradipta AR, Kawabe H, Lobsiger N, Tanaka K, Zako T (2021) Inhibition of amyloid formation of amyloid \u03b2 (1\u201342), amylin and insulin by 1, 5-diazacyclooctanes, a spermine-acrolein conjugate. Bioorg Med Chem 46:116391","journal-title":"Bioorg Med Chem"},{"issue":"2","key":"10754_CR123","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/ddr.10074","volume":"56","author":"C Adessi","year":"2002","unstructured":"Adessi C, Soto C (2002) Beta-sheet breaker strategy for the treatment of Alzheimer\u2019s disease. Drug Dev Res 56(2):184\u2013193","journal-title":"Drug Dev Res"},{"issue":"10","key":"10754_CR124","doi-asserted-by":"crossref","first-page":"17935","DOI":"10.1002\/jcb.29061","volume":"120","author":"S Shuaib","year":"2019","unstructured":"Shuaib S, Narang SS, Goyal D, Goyal B (2019) Computational design and evaluation of \u03b2-sheet breaker peptides for destabilizing Alzheimer\u2019s amyloid-\u03b242 protofibrils. J Cell Biochem 120(10):17935\u201317950","journal-title":"J Cell Biochem"},{"issue":"3","key":"10754_CR125","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1006\/bbrc.1996.1413","volume":"226","author":"C Soto","year":"1996","unstructured":"Soto C, Kindy MS, Baumann M, Frangione B (1996) Inhibition of Alzheimer\u2019s amyloidosis by peptides that prevent \u03b2-sheet conformation. Biochem Biophys Res Commun 226(3):672\u2013680","journal-title":"Biochem Biophys Res Commun"},{"issue":"7","key":"10754_CR126","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/nm0798-822","volume":"4","author":"C Soto","year":"1998","unstructured":"Soto C, Sigurdsson EM, Morelli L, Asok Kumar R, Casta\u00f1o EM, Frangione B (1998) \u03b2-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer\u2019s therapy. Nat Med 4(7):822\u2013826","journal-title":"Nat Med"},{"issue":"9199","key":"10754_CR127","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S0140-6736(99)11419-3","volume":"355","author":"C Soto","year":"2000","unstructured":"Soto C, Kascsak RJ, Sabor\u00edo GP, Aucouturier P, Wisniewski T, Prelli F et al (2000) Reversion of prion protein conformational changes by synthetic b-sheet breaker peptides. The Lancet 355(9199):192\u2013197","journal-title":"The Lancet"},{"issue":"16","key":"10754_CR128","doi-asserted-by":"crossref","first-page":"13905","DOI":"10.1074\/jbc.M211976200","volume":"278","author":"C Adessi","year":"2003","unstructured":"Adessi C, Frossard M-J, Boissard C, Fraga S, Bieler S, Ruckle T et al (2003) Pharmacological profiles of peptide drug candidates for the treatment of Alzheimer\u2019s disease. J Biol Chem 278(16):13905\u201313911","journal-title":"J Biol Chem"},{"issue":"16","key":"10754_CR129","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1002\/cbic.201600243","volume":"17","author":"A Sinopoli","year":"2016","unstructured":"Sinopoli A, Giuffrida A, Tomasello MF, Giuffrida ML, Leone M, Attanasio F et al (2016) Ac-LPFFD-Th: a trehalose-conjugated peptidomimetic as a strong suppressor of amyloid-\u03b2 oligomer formation and cytotoxicity. ChemBioChem 17(16):1541\u20131549","journal-title":"ChemBioChem"},{"key":"10754_CR130","doi-asserted-by":"crossref","unstructured":"Khairnar BD, Padhye A, Madiwal V, Jha A, Jadhav SH, Rajwade JM. Cyclic \u03b2-hairpin peptide loaded PLGA nanoparticles: a potential anti-amyloid therapeutic. Materials Today Communications. 2023:106322.","DOI":"10.1016\/j.mtcomm.2023.106322"},{"key":"10754_CR131","doi-asserted-by":"crossref","first-page":"116017","DOI":"10.1016\/j.bmc.2021.116017","volume":"33","author":"N Ghosh","year":"2021","unstructured":"Ghosh N, Kundu LM (2021) In-situ side-chain peptide cyclization as a breaker strategy against the amyloid aggregating peptide. Bioorg Med Chem 33:116017","journal-title":"Bioorg Med Chem"},{"issue":"11","key":"10754_CR132","doi-asserted-by":"crossref","first-page":"572","DOI":"10.3390\/pharmaceutics11110572","volume":"11","author":"F Pederzoli","year":"2019","unstructured":"Pederzoli F, Ruozi B, Duskey J, Hagmeyer S, Sauer AK, Grabrucker S et al (2019) Nanomedicine against A\u03b2 aggregation by \u03b2\u2013sheet breaker peptide delivery: In vitro evidence. Pharmaceutics 11(11):572","journal-title":"Pharmaceutics"},{"key":"10754_CR133","first-page":"271","volume-title":"Stem cell-based therapeutic strategy in delaying prion disease","author":"SK Metkar","year":"2021","unstructured":"Metkar SK, Girigoswami K, Girigoswami A (2021) Stem cell-based therapeutic strategy in delaying prion disease. Elsevier, Stem Cells and Aging, pp 271\u2013280"},{"issue":"4","key":"10754_CR134","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.3390\/ani11041137","volume":"11","author":"L Garc\u00eda-Mend\u00edvil","year":"2021","unstructured":"Garc\u00eda-Mend\u00edvil L, Mediano DR, Hernaiz A, Sanz-Rubio D, V\u00e1zquez FJ, Mar\u00edn B et al (2021) Effect of scrapie prion infection in ovine bone marrow-derived mesenchymal stem cells and ovine mesenchymal stem cell-derived neurons. Animals 11(4):1137","journal-title":"Animals"},{"issue":"11","key":"10754_CR135","doi-asserted-by":"crossref","first-page":"5918","DOI":"10.1128\/JVI.00165-09","volume":"83","author":"C-H Song","year":"2009","unstructured":"Song C-H, Honmou O, Ohsawa N, Nakamura K, Hamada H, Furuoka H et al (2009) Effect of transplantation of bone marrow-derived mesenchymal stem cells on mice infected with prions. J Virol 83(11):5918\u20135927","journal-title":"J Virol"},{"issue":"11","key":"10754_CR136","doi-asserted-by":"crossref","first-page":"4168","DOI":"10.3390\/ijms21114168","volume":"21","author":"S Martellucci","year":"2020","unstructured":"Martellucci S, Santacroce C, Santilli F, Manganelli V, Sorice M, Mattei V (2020) Prion protein in stem cells: a lipid raft component involved in the cellular differentiation process. Int J Mol Sci 21(11):4168","journal-title":"Int J Mol Sci"},{"key":"10754_CR137","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2021.113706","volume":"341","author":"AF Neves","year":"2021","unstructured":"Neves AF, Camargo C, Premer C, Hare JM, Baumel BS, Pinto M (2021) Intravenous administration of mesenchymal stem cells reduces Tau phosphorylation and inflammation in the 3xTg-AD mouse model of Alzheimer\u2019s disease. Exp Neurol 341:113706","journal-title":"Exp Neurol"},{"issue":"1","key":"10754_CR138","first-page":"1","volume":"13","author":"HJ Kim","year":"2021","unstructured":"Kim HJ, Cho KR, Jang H, Lee NK, Jung YH, Kim JP et al (2021) Intracerebroventricular injection of human umbilical cord blood mesenchymal stem cells in patients with Alzheimer\u2019s disease dementia: A phase I clinical trial. Alzheimer\u2019s Res Ther 13(1):1\u201311","journal-title":"Alzheimer\u2019s Res Ther"},{"issue":"9","key":"10754_CR139","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.3390\/cells10092377","volume":"10","author":"B Fernandez-Mu\u00f1oz","year":"2021","unstructured":"Fernandez-Mu\u00f1oz B, Garcia-Delgado AB, Arribas-Arribas B, Sanchez-Pernaute R (2021) Human neural stem cells for cell-based medicinal products. Cells 10(9):2377","journal-title":"Cells"},{"key":"10754_CR140","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.ijbiomac.2020.01.219","volume":"148","author":"M Zarei-Kheirabadi","year":"2020","unstructured":"Zarei-Kheirabadi M, Sadrosadat H, Mohammadshirazi A, Jaberi R, Sorouri F, Khayyatan F et al (2020) Human embryonic stem cell-derived neural stem cells encapsulated in hyaluronic acid promotes regeneration in a contusion spinal cord injured rat. Int J Biol Macromol 148:1118\u20131129","journal-title":"Int J Biol Macromol"},{"key":"10754_CR141","doi-asserted-by":"crossref","first-page":"650103","DOI":"10.3389\/fnagi.2021.650103","volume":"13","author":"M-H Lu","year":"2021","unstructured":"Lu M-H, Ji W-L, Chen H, Sun Y-Y, Zhao X-Y, Wang F et al (2021) Intranasal transplantation of human neural stem cells ameliorates Alzheimer\u2019s disease-like pathology in a mouse model. Frontiers in Aging Neurosci 13:650103","journal-title":"Frontiers in Aging Neurosci"},{"issue":"8","key":"10754_CR142","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.stemcr.2023.05.003","volume":"18","author":"T Hirai","year":"2023","unstructured":"Hirai T, Yasuda S, Umezawa A, Sato Y (2023) Country-specific regulation and international standardization of cell-based therapeutic products derived from pluripotent stem cells. Stem Cell Rep 18(8):1573\u20131591","journal-title":"Stem Cell Rep"},{"key":"10754_CR143","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.neurobiolaging.2018.01.004","volume":"65","author":"K Frid","year":"2018","unstructured":"Frid K, Binyamin O, Fainstein N, Keller G, Ben-Hur T, Gabizon R (2018) Autologous neural progenitor cell transplantation into newborn mice modeling for E200K genetic prion disease delays disease progression. Neurobiol Aging 65:192\u2013200","journal-title":"Neurobiol Aging"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-10754-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-025-10754-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-10754-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T12:14:53Z","timestamp":1779797693000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-025-10754-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,4]]},"references-count":143,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10754"],"URL":"https:\/\/doi.org\/10.1007\/s11033-025-10754-2","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,4]]},"assertion":[{"value":"21 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}],"article-number":"674"}}